Svitlana Demyanets


Affiliation: Medical University of Vienna
Country: Austria


  1. Kieler M, Unseld M, Wojta J, Kaider A, Bianconi D, Demyanets S, et al. Plasma levels of interleukin-33 and soluble suppression of tumorigenicity 2 in patients with advanced pancreatic ductal adenocarcinoma undergoing systemic chemotherapy. Med Oncol. 2018;36:1 pubmed publisher
    ..10, 95% CI 1.33-3.41, p = 0.002) and link high sST2 plasma levels to inferior survival in patients with advanced PDAC undergoing chemotherapy. ..
  2. Eilenberg W, Stojkovic S, Piechota Polanczyk A, Kaun C, Rauscher S, Gröger M, et al. Neutrophil Gelatinase-Associated Lipocalin (NGAL) is Associated with Symptomatic Carotid Atherosclerosis and Drives Pro-inflammatory State In Vitro. Eur J Vasc Endovasc Surg. 2016;51:623-31 pubmed publisher
  3. Montanari E, Stojkovic S, Kaun C, Lemberger C, de Martin R, Rauscher S, et al. Interleukin-33 stimulates GM-CSF and M-CSF production by human endothelial cells. Thromb Haemost. 2016;116:317-27 pubmed publisher
  4. Demyanets S, Tentzeris I, Jarai R, Katsaros K, Farhan S, Wonnerth A, et al. An increase of interleukin-33 serum levels after coronary stent implantation is associated with coronary in-stent restenosis. Cytokine. 2014;67:65-70 pubmed publisher
    ..In patients with both stable and unstable coronary artery disease, an increase of IL-33 serum levels after stent implantation is associated with a higher rate of in-stent restenosis. ..
  5. Krychtiuk K, Stojkovic S, Lenz M, Brekalo M, Huber K, Wojta J, et al. Predictive value of low interleukin-33 in critically ill patients. Cytokine. 2018;103:109-113 pubmed publisher
    ..Both together showed additive predictive value suggesting a pathogenic role of the IL-33/ST2 system in critically ill patients. ..